Clinical Trial Update: Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating LAG525 as a single agent and in combination with PDR001 in patients with advanced solid tumors; results have been posted after comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• LAG525
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-10